Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Additional value of the 70-gene signature and levels of ER and PR for the prediction of outcome in tamoxifen-treated ER-positive breast cancer.

Breast (Edinburgh, Scotland) - 1 Dec 2012

Kok M, Koornstra R H, Mook S, Hauptmann M, Fles R, Jansen M P, Berns E M, Linn S C, Van 't Veer L J

Abstract excerpt

BACKGROUND: Breast cancer patients with node positive disease can have an excellent outcome with tamoxifen only. It is unclear whether analysing both the 70-gene signature and hormone receptors provides superior prediction of outcome in tamoxifen-treated patients than either alone. METHODS: Three series were evaluated: 121 patients (81% node positive) received adjuvant tamoxifen, 151 patients did not receive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Follow-Up Studies

Share to Mastectomy

Share to Receptors, Estrogen

Share to Receptors, Progesterone

Share to Survival Analysis

Share to Tamoxifen

Source

Identifiers

PMID: 22738860
DOI: 10.1016/j.breast.2012.04.010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Additional value of the 70-gene signature and levels of ER and PR for the prediction of outcome in tamoxifen-treated ER-positive breast cancer.PMID 22738860Read ↗

Additional value and potential use of the 70-gene prognosis signature in node-negative breast cancer in daily clinical practice.Semantic proximity Read ↗

Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast CancerSemantic proximity Read ↗

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.Semantic proximity Read ↗

Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signatureSemantic proximity Read ↗

The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancerSemantic proximity Read ↗

The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of ageSemantic proximity Read ↗

Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trialSemantic proximity Read ↗

The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation studySemantic proximity Read ↗

An 8-gene qRT-PCR-based gene expression score that has prognostic value in early breast cancer.Semantic proximity Read ↗

Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast CancerSemantic proximity Read ↗

Miller–Payne Grading and 70-Gene Signature Are Associated With Prognosis of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer After Neoadjuvant ChemotherapySemantic proximity Read ↗

A prospective evaluation of a breast cancer prognosis signature in the observational RASTER studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.